The present invention is directed to treatments for a
disease or condition, in a subject in need thereof, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100%
treatment compliance, reduced side effects, and rapid establishment and / or termination of substantial steady-state
drug delivery. The method includes providing
continuous delivery of a
drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the
drug at therapeutic concentrations is achieved within about 7 days after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2
diabetes mellitus using insulinotrophic peptides. In embodiments, a subject has a baseline HbA1c % of greater than 6.5% or 10.0%.